ClinicalTrials.gg
Not yet recruitingNCT07910903Updated Nov 2, 2026

Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma

A Phase 3 interventional study of CM336 and CM313 in Multiple Myeloma (MM), sponsored by Keymed Biosciences Co.Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Keymed Biosciences Co.Ltd · Phase 3, Interventional, and Treatment

Updated Nov 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
38th of 406
320 · median 40
Started
2026
with 53 others
Phase 3
66 of 448
24 open now
Primary completion
2030-05
later than 259 of 274 live
Registered
446th of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 38th largest by planned enrollment of the 406 interventional ones that give a count, is one of 54 that started in 2026, is one of 66 in phase 3, reaches primary completion later than 259 of the 274 other live ones, and was the 446th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

This study consists of two parts. The purpose of Part 1 is to evaluate the safety and tolerability of CM336+CM313 combination therapy in participants with relapsed or refractory multiple myeloma (RRMM). Part 2 is to compare the efficacy of CM336 + CM313 (Group A) with Daratumumab + Pomalidomide +Dexamethasone (DPd) (Group B) in RRMM patients.

03

Conditions studied

  • Multiple Myeloma (MM)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form.
  • Age ≥18 years. Gender is not limited.
  • (ECOG) performance status score of 0 to 2.
  • Participants with multiple myeloma (RRMM) who have received 1 to 3 , including at least one proteasome inhibitor and one immunomodulatory drug.
  • Investigator-assessed evidence of disease progression or failure to achieve response after the last line of therapy, according to the International Myeloma Working Group (2016IMWG) criteria.
  • at screening, defined by at least one of the following:

    1. Serum M-protein≥5 g/L;
    2. Urine M-protein≥200 mg/24 h;
    3. Involved serum FLC level≥100 mg/L with an abnormal κ/λ ratio.

Exclusion criteria

Exclusion Criteria:

  • Received any prior B cell maturation antigen (BCMA)-targeted therapy.
  • IMWG-defined disease to anti-CD38 therapy.
  • Participants are not eligible to receive DPd as control therapy if any of the following are present: , life-threatening , or intolerance to pomalidomide.
  • Participants with primary light-chain amyloidosis (AL), plasma cell leukemia, Waldenström macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or solitary plasmacytoma.
  • Received a cumulative dose of equivalent to ≥140 mg of prednisone within 14 days before randomization.
  • Received a live, attenuated vaccine within 4 weeks before randomization.
  • Contraindication, intolerance, or life-threatening allergy to any product or .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    Part 1:CM336+CM313

    Drug: CM336 · Drug: CM313

  • Experimental
    Part 2,Arm A: CM336+CM313

    Drug: CM336 · Drug: CM313

  • Active comparator
    Part 2,Arm B: Daratumumab + Pomalidomide +Dexamethasone

    Drug: Daratumumab · Drug: Pomalidomide · Drug: Dexamethasone

  • Experimental
    Part 2,Arm C: CM336

    Drug: CM336

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Frequency of Adverse Events (AEs)

    An adverse event is any untoward medical occurrence in a study participant receiving study product, whether or not related to the product. Severity graded per CTCAE version 6.0.

    Time frame: Up to 4 years

  2. Part 2: 9-Month Minimal Residual Disease (MRD) Negative Complete Response (CR)

    MRD negative CR at Month 9 (±3 months) is defined as participants who have MRD negative status at Month 9±3 months (prior to progression or subsequent antimyeloma therapy) and have achieved CR or better per IMWG criteria at any time post-randomization up to Month 9±3 months.

    Time frame: At month 9

  3. Part 2: Progression Free Survival (PFS)

    PFS is defined as the duration from the date of randomization to disease progression or death, whichever occurs first. Disease progression will be assessed according to IMWG criteria.

    Time frame: Up to 4 years

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for May 2030, 41 months later.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 41 months is close to that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 2, 2026
StartEst.
Dec 2026
Primary completionEst.
May 2030
CompletionEst.
Nov 2030
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07910903
Responsible party
Sponsor
First posted
Nov 2, 2026
Start date
Dec 2026 (estimated)
Primary completion
May 2030 (estimated)
Completion
Nov 2030 (estimated)
Last update
Nov 2, 2026

Study contacts

Qian Jia
Contact
clinicaltrial@keymedbio.com
028-88610620

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CM336 · Lumrotatug

Start the discussion